Single puncture bifurcation graft deployment system

Abstract
The present invention relates to the endoluminal repair of abdominal aortic aneurysms at the aortic and iliac bifurcation. In particular, a deployment system and graft are disclosed for deploying the bifurcated graft within both iliac branches, as well as the aortic trunk, from a single vascular access.
Description
BACKGROUND OF THE INVENTION

The present invention relates to the endoluminal repair of abdominal aortic aneurysms at the aortic and iliac bifurcation, and more particularly, to a deployment system used to deploy a self-expanding prosthesis.


Endoluminal repair or exclusion of aortic aneurysms has been performed for the past several years. The goal of endoluminal aortic aneurysm exclusion has been to correct this life threatening disease in a minimally invasive manner in order to effectuate a patient's quick and complete recovery. Various vascular grafts exist in the prior art that have been used to exclude aortic aneurysms. These prior art grafts have met varying degrees of success.


Initially, straight tube grafts were used in the infrarenal abdominal aorta to exclude the aneurysmal sac from the blood stream thereby resulting in the weakened aortic wall being protected by the graft material. These straight tube grafts were at first unsupported, meaning that they employed stents at their proximal and distal ends to anchor the proximal and distal ends of the graft to the healthy portions of the aorta, thereby leaving a midsection of the graft or prosthesis that did not have any internal support. Although this type of graft at first appeared to correct the aortic aneurysm, it met with many failures. The unsupported nature of its midsection allowed the graft to migrate distally as well as exhibit significant proximal leakage due to the enlargement of the aorta without adaptation of the graft, such as enlargement of the graft, to accommodate the change in diameter of the aorta.


Later, technical improvements in stent design led to “self-expanding” stents. In addition, later improvements produced “Nitinol” stents that had a “memory” that was capable of expanding to a predetermined size. Coincidentally, graft designers began to develop bifurcated grafts having limbs that extended into the iliac arteries. The development of bifurcated grafts allowed for the treatment of more complex aneurysms. With the advent of bifurcated grafts, the need for at least a 1.0 cm neck from the distal aspect of the aneurysmal sac to the iliac bifurcation in order to treat the aneurysm with an endoluminal graft was no longer needed. However, proximal necks of at least 0.5 to 1.0 cm distance from the renal arteries to the most proximal aspect of the aneurysm are still generally required.


Some bifurcated grafts are of a two-piece design, in which an aorta and ipsilateral iliac segment is connected with a contralateral iliac branch in situ. The two-piece designs require the insertion of a contralateral limb through a separate access site. These types of grafts are complex to deploy and have the potential for leakage at the connection site of the two limbs of the graft.


One-piece bifurcated grafts are also known in the art. For example, U.S. Pat. No. 2,845,959 discloses a one-piece seamless woven textile bifurcated tube for use as an artificial artery. Yams of varying materials can be used to weave the bifurcated graft including nylon and plastic yams. U.S. Pat. Nos. 3,096,560 and 3,029,9819 issued to Liebig and Starks, respectively, disclose woven one-piece bifurcated grafts which are constructed by performing specific types of winding and weaving about a smooth bifurcated mandrel.


U.S. Pat. No. 4,497,074 describes a one-piece bifurcated graft that is made from a preformed support in the shape of the bifurcated graft. In a first stage, a gel enabling a surface state close to that of the liquid-air interface to be obtained at the gel-air interface is deposited by dipping or coating the preform with a sol which is allowed to cool. A hardenable flexible material such as a silicone elastomer is applied by dipping or spraying the material on the mold in a second stage. Finally, after hardening of the material, the prosthesis is removed from the mold. In U.S. Pat. No. 4,816,028 issued to Kapadia et al., there is shown a one-piece woven bifurcated vascular graft having a plurality of warp threads running in the axial direction and a plurality of weft threads running in the transverse direction. Further, U.S. Pat. No. 5,108,424 issued to Hoffman, Jr. et al. discloses a one-piece bifurcated collagen-impregnated Dacron graft. The bifurcated graft includes a porous synthetic vascular graft substrate formed by knitting or weaving with at Cast three applications of dispersed collagen fibrils.


The Herweck et al. U.S. Pat. No. 5,197,976, discloses a continuous one-piece bifurcated graft having plural longitudinally parallel tube structures which are attached to one another over at least a portion of their longitudinal exteriors. The tube structures can be manually separated to form a branched tubular structure. The prosthesis is manufactured by paste forming and stretching and/or expanding highly crystalline unsintered polytetrafluoroethylene (PTFE). Paste forming includes mixing the PTFE resin with a lubricant, such as mineral spirits, and then forming the resin by extrusion into shaped articles.


Although all of the above-described one-piece bifurcated grafts have eliminated the problems of leakage and graft failure at the suture or juncture site associated with two piece bifurcated grafts which join together two separate grafts to form the bifurcated graft, problems still exist with these one-piece bifurcated grafts. For example, the previously described one-piece bifurcated grafts do not include an integral support structure to prevent the deformation, twisting or collapse of the graft limbs. Further, the same problems with graft migration that existed with straight tube grafts still exist with the one-piece bifurcated grafts. Accordingly, there is a need for a stable and durable transluminally implantable bifurcated vascular graft that is structured to prevent the migration and deformation of the graft and obstruction of the blood flow through the limbs of the bifurcated graft.


Endoluminal implantation is an increasingly accepted technique for implanting vascular grafts. Typically, this procedure involves percutaneously inserting a vascular graft or prosthesis by using a delivery catheter. This process eliminates the need for major surgical intervention thereby decreasing the risks associated with vascular and arterial surgery. Various catheter delivery systems for prosthetic devices are described in the prior art.


For example, bifurcated vascular grafts have been created by combining grafts with stents on delivery systems in order to secure the graft ends to the blood vessel thereby stabilizing the bifurcated graft. In U.S. Pat. No. 5,360,443 issued to Barone et al., a method for repairing an abdominal aortic aneurysm is described. The method comprises the steps of (1) connecting an expandable and deformable tubular member, such as a stent, to each of the tubular passageways of a bifurcated graft, (2) disposing the bifurcated graft and deformable tubular members within the aortic and iliac arteries, and (3) expanding and deforming each deformable tubular member with a catheter to secure each tubular passageway of the bifurcated graft within the appropriate artery. This reference only discloses a catheter delivery method for deploying the aortic portion of the bifurcated graft. The same catheter is supposedly used to also expand and secure the associated stents within the iliac arteries.


The Palmaz et al. U.S. Pat. No. 5,316,023, describes a method and apparatus for repairing an abdominal aortic aneurysm in an aorta at the iliac arteries. This method includes the steps of connecting a first tubular graft to a first deformable and expandable tubular member, connecting a second tubular graft to a second deformable and expandable tubular member, disposing the first tubular graft and first tubular member upon a first catheter having an inflatable portion, disposing the second tubular graft and second tubular member upon a second catheter having an inflatable portion, intraluminally delivering the first and second tubular grafts, tubular members and catheters to the aorta and disposing at least a portion of each tubular graft within the abdominal aortic aneurysm, and expanding the tubular members with the inflatable catheters to secure them and at least a portion of their associated tubular grafts within the aorta. This patent reference employs two separate unconnected straight grafts that are employed within an aorta to form a bifurcated graft.


Further, U.S. Pat. No. 4,617,932 issued to Komberg discloses a device for inserting a graft into an artery comprising a plurality of nested tubes each having an upper and lower end. A first outer tube has a means for guiding and positioning an arm means at its, upper end. The arm means is movably attached to the upper end of another tube located inside of the first tube and extending above the first outer tube. The lower ends of the tubes are adaptable for fastening means and the inside tube extends below the end of the first outer tube. Delivery and placement of a bifurcated graft is illustrated. U.S. Pat. No. 5,522,883 issued to Slater et al. describes an endoprosthesis stent/graft deployment system which includes a tubular delivery catheter, a radially expandable prosthesis positioned over the catheter, a removable endoprosthesis support assembly located adjacent the catheter opening and having an arm extending through the catheter which keeps the endoprosthesis in a compressed state, and a release mechanism insertable through the catheter for removing the support assembly.


U.S. Pat. No. 5,104,399 issued to Lazarus also describes an artificial graft and delivery method. The delivery system includes a capsule for transporting the graft through the blood vessel, a tube connected to the vessel that extends exterior to the vessel for manipulation by a user, and a balloon catheter positioned within the tube. Finally, U.S. Pat. No. 5,489,295 issued to Piplani et al. discloses a bifurcated graft and a method and apparatus for deploying the bifurcated graft. The Piplani et al. graft includes a main tubular body, first and second tubular legs joined to the main tubular body in a bifurcation, a first expandable attachment means for anchoring the main body located adjacent the opening for the first body, and a second expandably attachment means located adjacent the opening of the first tubular leg for anchoring the first tubular leg. The graft is intraluminally implanted using a catheter that is inserted into the aortic bifurcation through a first iliac artery so that the first attachment means adjacent the opening of the main body can be anchored in the aorta and the second attachment means adjacent the opening of the first tubular leg can be anchored in the first iliac artery. The second tubular leg is deployed into the second iliac artery by using a pull line attached to the second tubular leg. The Piplani et al. patent also discloses a deployment device consisting of a capsule catheter, a balloon catheter, and a separate expandable spring attachment means.


None of the described methods and devices permits delivery of a one-piece bifurcated graft from a single access site. Indeed, current procedures require a double or triple cut-down or percutaneous access to the left and right femoral and/or brachial arteries to insert catheters, guidewires, and guide catheters. Accordingly, not only is there a need for an improved structurally supported self expandable one piece bifurcated graft, but there is also a need for a delivery apparatus and method for deploying and implanting such a bifurcated graft from a single access site.


SUMMARY OF THE INVENTION

There is disclosed in accordance with the present invention a deployment system for deploying a bifurcated prosthesis at the junction of a main vessel and first and second branch vessels. The system comprises a delivery catheter and a bifurcated prosthesis. The delivery catheter has an inner core connected to a tubular housing and slidably positioned within a middle core. The middle core has proximal and distal ends and at least the distal end of the middle core forms a tubular sheath. The middle core is slidably positioned within an outer sheath. The bifurcated prosthesis in accordance with the deployment system of the present invention has a main body section with proximal and distal ends and first and second branch sections at the proximal end of the main body section. The main body section is held in a radially compressed state within the tubular housing of the inner core. The first branch section is held in a radially compressed state within the tubular sheath of the middle core. And the second branch section is disposed within the outer sheath in a radially compressed state.


A method is disclosed for deploying bifurcated endoluminal prosthesis at the junction of a main vessel, such as the aorta, and first and second branch vessels, such as the ipsilateral and contralateral iliac arteries. A deployment system is introduced through an access site into the first branch vessel and advanced distally (catheter direction) through at least a portion of the first branch vessel and into the main vessel. The deployment system contains a bifurcated prosthesis comprising a main body section and first and second branch sections. The proximal end of the second branch section is extended outward from the deployment system into the main vessel in the direction of the second branch vessel by proximally retracting an outer sheath of the deployment system. The extended second branch section is positioned within the second branch vessel by proximally retracting the deployment system.


The first branch section of the prosthesis is expanded from a radially compressed state within the deployment system to a radially expanded state within the first branch vessel by proximally retracting a middle core of the deployment system. The main body section of the prosthesis is expanded from a radially compressed state within the deployment system to a radially expanded state within the main vessel by distally advancing an inner core of the deployment system. The second branch section within the second branch vessel is expanded and the deployment system is retracted distally through a central lumen in the main body and first branch sections of the prosthesis and oat of the patient's body.


In one embodiment of the disclosed method, the second branch section comprises a wire support formed from a memory alloy. Consequently, the second branch section may be expanded by heating the wire support.


Alternatively, the second branch section may comprise a self-expandable wire support, which is mechanically restrained in a radially compressed state by a restraint. The second branch section is then expanded by removing the restraint. The restraint may comprise any of a variety of structures, such as a wire woven through or around the collapsed second branch or a sheath around the collapsed second branch. In one embodiment, the sheath is peelable or tearable so that it can be removed by retraction in the proximal catheter direction. The second branch section is expanded by axially moving the wire or sheath.


Further features and advantages of the present invention will become apparent to those of skill in the art in view of the disclosure herein, when considered together with the attached drawings and claims.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic representation of the deployment system of the present invention positioned within the ipsilateral iliac and the aorta.



FIG. 2 is a schematic representation of the deployment system of the present invention positioned within the ipsilateral iliac and the aorta, showing separation of the contralateral limb from the ipsilateral limb.



FIG. 3 is a schematic representation of the deployment system of the present invention illustrating positioning of the ipsilateral and contralateral limbs of the bifurcated graft within the respective iliac branches by proximal retraction of the deployment catheter.



FIG. 4 is a schematic representation of the deployment system of the present invention showing deployment of the ipsilateral limb of the bifurcated graft by withdrawal of the middle core.



FIG. 5 is a schematic representation of the deployment system of the present invention showing a segmented configuration of the middle core.



FIG. 6 is a schematic representation of the deployment system of the present invention showing deployment of the main body of the bifurcated graft by distally advancing the inner core.



FIG. 7 is a schematic representation of the deployment system of the present invention illustrating deployment of the contralateral limb of the bifurcated graft by applying heat, in the illustrated embodiment to the memory alloy wire cage of the contralateral limb.



FIG. 8 is a schematic representation of the deployment system of the present invention showing withdrawal of the deployment catheter of the present invention from the fully deployed graft.



FIG. 9 is a schematic representation of the fully deployed graft of the present invention in situ.



FIG. 10 is a schematic representation of a variation of the deployment system of the present invention showing retention of a self-expanding contralateral limb with a small diameter filament.



FIG. 11 is a schematic representation of another variation of the deployment system of the present invention showing a contralateral limb sheath.



FIG. 12 is a schematic representation of the deployment system of FIG. 11, showing deployment of the contralateral limb by proximal retraction of a deployment wire.



FIG. 13 is a schematic representation of a variation of the deployment system of the present invention, showing retention of the contralateral limb by a peel-away limb cover.



FIG. 13A is an enlarged view of a peel-away contralateral limb cover in accordance with the present invention.



FIG. 14 is a schematic representation of the system of FIG. 13, ready for deployment of the contralateral limb.



FIG. 15 is a representation of the system of FIG. 14, with the contralateral limb partially deployed.



FIG. 16 is a representation as in FIG. 15, with the contralateral limb fully deployed.



FIG. 17 is a representation of the system as in FIG. 16, with the ipsilateral limb deployed.



FIG. 18 is an exploded view of a bifurcated graft in accordance with the present invention, showing a self expandable wire cage separated from an outer polymeric sleeve.



FIG. 19 is schematic representation of the bifurcated graft in accordance with one embodiment of the present invention, showing an expansion spring.



FIG. 20 is plan view of a formed wire useful for rolling into a multi-segmented wire cage in accordance with the present invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

This invention relates to a delivery catheter and graft system for deploying a bifurcated vascular graft, which allows deployment of the graft from a single vascular access site. A related technique using two access sites is disclosed in co-pending patent application Ser. No. 08/802,478 entitled Bifurcated Vascular Graft and Method and Apparatus for Deploying Same, filed Feb. 20, 1997, the disclosure of which is incorporated in its entirety herein by reference.


Referring to FIG. 1, an embodiment of the deployment system 10 is depicted in situ at the bifurcation of the aorta into the ipsilateral iliac 20 (in which the deployment system 10 resides) and the contralateral iliac 26. In general, the illustrated deployment system 10 employs an over-the-wire coaxial design with three inter-moving elements and, in one embodiment, a thermal or electrical conduit as will be described. The deployment system 10 is percutaneously (or surgically) inserted into a first access site such as a femoral artery puncture (not illustrated). The system 10 is advanced distally along a guidewire through the ipsilateral iliac 20 and into the aorta 22, until positioned as generally illustrated in FIG. 1, spanning the site of an aortic aneurysm 24.


In an embodiment intended for femoral artery access to deploy an abdominal aortic aneurysm bifurcation graft, the deployment system 10 has an overall length from proximal to distal end generally within the range of from about 90 cm to about 110 cm. As used herein, the relative terms “proximal” and “distal” shall be defined from the perspective of the delivery system 10. Thus, proximal is in the direction of the control end of the system (not illustrated) and distal is in the direction of the distal tip 32.


The illustrated deployment system 10 includes an inner core 30, a middle core 40, an outer sheath 50, and a contralateral graft actuator 60. The inner core 30 is preferably a thin-walled tube designed to track over a guidewire, such as a standard 0.035 inch guidewire. In the illustrated embodiment, the inner core 30 preferably has as small an outside diameter as possible to minimize the overall outside diameter of the delivery catheter, while at the same time providing sufficient column strength to permit distal axial advancement of the tapered tip 32 and tubular housing 33 to deploy the main trunk of the prosthesis as will be discussed. A section of stainless steel hypotube having an inside diameter of about 0.042 inches, an outside diameter of about 0.058 inches, and an overall length of about 95 cm, depending upon the length of the delivery catheter, has been found suitable for this purpose.


The device 10 has a soft tapered tip 32 secured to the distal end of inner core 30. Tapered tip 32 facilitates insertion and atraumatic navigation of the vasculature. The tapered tip 32 can be made from any of a variety of polymeric materials well known in the medical device arts, such as polyethylene, nylon, PTFE, and PEBAX.


The distal tapered tip 32 tapers in one embodiment from an outside diameter of about 0.225 inches at its proximal end to an outside diameter of about 0.070 inch at its distal end. The overall length of the distal tip 32 in one embodiment of the deployment system 10 is about 3 inches. However, the length and rate of taper of the distal tip 32 can be varied within the range of from about ½ inch to about 4 or 5 inches, depending upon the desired tractability and flexibility characteristics.


A tubular housing 33 extends proximally from and is attached to or is a proximal extension of the distal tip 32. The tubular housing 33 and distal tip 32 are connected to the inner core 30, so that distal advancement of the inner core 30 will also distally advance the tip 32 and housing 33. The tubular housing 33 serves as a sheath for retaining the compressed main body of the bifurcated graft of the present invention. In one embodiment, the tubular housing 33 comprises a polyolefin extrusion having a length of about 15 cm an inside diameter of about 0.210 inches and an outside diameter of about 0.225 inches.


The distal end of the tubular housing 33 is secured to the proximal end of the distal tip 32 such as by heat shrinking, thermal bonding, adhesive bonding, and/or any of a variety of other securing techniques known in the art. Alternatively, the tip 32 and housing 33 may be integrally formed such as by extrusion followed by heated stretching or other technique to taper the distal end. The distal tip 32 is preferably also directly or indirectly connected to the inner core 30 such as by a friction fit, adhesives or thermal bonding.


The middle core 40 comprises an elongate flexible tubular body adapted to axially slidably track over the inner core 30. In the illustrated embodiment, the middle core 40 comprises a polyethylene or PTFE extrusion having an inside diameter of about 0.180 inches and an outside diameter of about 0.220 inches. The inner and/or outer surfaces of the middle core 40 may be further provided with a lubricious coating such as paralene, silicone, PTFE or others well known in the art.


The middle core 40 has a tubular distal end to slidably receive ipsilateral iliac limb 72 of the graft as will be discussed (See, e.g., FIGS. 3 and 4). The middle core 40 may be tubular throughout its length, or may comprise a pull wire or ribbon throughout a proximal portion thereof (See, e.g., FIG. 5). The tubular distal segment has an axial length of at least about 5 cm or longer depending upon the dimensions of the graft.


The outer core 50 comprises an elongate, flexible tubular body, slidably positioned over the middle core 40. Outer core 50 also entraps the restrained contralateral limb against the outside surface of middle core 40 in the illustrated embodiment.


In one embodiment, the outer sheath 50 comprises extruded PTFE, having an Outside diameter of about 0.250 inches and an inside diameter of about 0.230 inches. The outer sheath 50 has an axial length within the range of from about 40 inches to about 55 inches. In the loaded configuration illustrated in FIG. 1, the distal end 52 of the outer sheath 50 is located at least about 16 cm proximally of the distal end 34 of the tapered tip 32. The outer sheath 50 may be provided at its proximal end (not shown) with a manifold, having a hemostatic valve and access ports, such as for the infusion of drugs or contrast media as will be understood by those of skill in the art.


With reference to FIG. 2, as the outer sheath 50 is retracted proximally, the contralateral limb 70 separates from the middle core 40 and inclines laterally due to the resilience of the wire cage in the contralateral limb 70. Alternatively, the limbs may separate due to an internal separation spring connected to the ipsilateral and contralateral limbs, with the apex of the spring located at the bifurcation. See, e.g., FIG. 14) The ipsilateral limb (hidden) remains sheathed by the middle core 40. The main body of the stent graft remains sheathed by the tubular housing 33.


The self-expandable ipsilateral limb 72 of the graft is deployed within the ipsilateral iliac 20, as illustrated in FIG. 4, by proximally retracting the middle core 40. In the embodiment shown in FIG. 4, the middle core 40 comprises a thin-walled length of PTFE tubing having an outside diameter of about 0.215 inches. The middle core 40 moves axially with respect to the inner core 30.


Referring to FIG. 5, a variation of the middle core 40 design consists of a relatively short ipsilateral sheath section 44, which is necked down such as by heat shrinking to secure the ipsilateral sheath section 44 to a longer tubular extension 46, the combination forming the modified middle core 40. As described above, the ipsilateral limb 72 of the graft is deployed by proximally withdrawing the tubular extension 46 so that retraction of the ipsilateral sheath section 44 releases the self-expandable wire cage from its compressed state in the ipsilateral limb 72. The length of sheath 44 is generally in the range of from about 5 cm to about 9 cm. In one embodiment in which the ipsilateral limb 72 has a length of about 5.5 cm, the sheath 44 has a length of about 5.5 cm.


Referring to FIG. 6, the self-expanding aortic trunk portion, or main body 74 of the graft 76 is released from its compressed state within the tubular housing 33 by distally advancing the inner core 30. Because the tubular housing 33 and distal tip 32 are attached to the inner core 30, the distal movement of the inner core causes the housing 33 to advance, thereby permitting the main body 74 of the graft to expand to its larger, deployed diameter.


As illustrated in FIG. 7, the contralateral limb 70 of the graft 76 may then be expanded within the contralateral iliac 26 by activation of the contralateral graft actuator 60. In an embodiment in which the contralateral graft comprises a memory metal, expansion may be accomplished by heating the contralateral limb via actuator 60. When the memory alloy support within the contralateral limb 70 reaches its transition temperature, which may be between 40-60.degree. C. for Nitinol, the compressed wire expands to its predetermined tubular shape.


In one embodiment, power from a DC power supply or RF generator is transferred to the wire support cage from the proximal end of the deployment system, by way of an electrically conductive graft actuator 60. Any of a wide variety of electrical conductors can be utilized for the electrically-conductive graft actuator 60, including solid wire, braided filaments and others as will be understood by those of skill in the art. In one embodiment, a solid wire having a cross section of about 0.010 inches and an insulating layer comprising polyimide and having a thickness of about 0.002 inches is utilized. The electrical conductor may contact the memory alloy wire of the graft via clasp, jaws, wire bending or intermeshing, a third segment, welds, or free contact. The electrically conductive actuator wire is preferably coated with a polymer material providing both electrical and thermal resistance. The thickness of the coating is preferably between about 0.001 inches to about 0.0015 inches. The polymer materials that can be used for the coating are materials such as PTFE, polyimide and polyester. The coating preferably provides insulation at temperatures ranging from about 20.degree. C. to about 60.degree. C. The electrical conductor is also retracted with the deployment system.


Referring to FIG. 8, the deployment system 10, including the distal tip 32 and tubular housing 33, the inner core 30 and middle core 40, and the actuator 60, are proximally retracted through the expanded bifurcated graft 76. The deployment system may thereafter be proximally withdrawn from the patient by way of the single vascular access site, leaving only the fully deployed bifurcated graft 76 spanning the aortic aneurysm 24 as shown in FIG. 9.


Any of a variety of structures can be utilized to restrain the contralateral limb 70, during placement of the graft, and thereafter release or expand the contralateral limb 70 within the contralateral iliac. Preferably, all such restraining and release mechanisms are operated through the single vascular access site as has been discussed. Thus, in embodiments using removable mechanical retention structures such as a sheath or restraining wire proximal (inferior anatomical direction) retraction of the restraining structure will release the ipsilateral limb, whereas proximal retraction of a release wire will advance the restraining structure in the superior anatomical direction to release the contralateral limb 70. A release wire shall mean any suitable structure including a wire or cord.


For example, a small diameter wire (e.g. 0.010 inch diameter) or low profile ribbon (e.g. 0.001 inch by 0.003 inch) restraint 100 may be wrapped or woven around a self-expanding stent cage to hold it in a collapsed profile for placement within the contralateral limb 70 as illustrated in FIG. 10. The main body 74 and ipsilateral limb 72 of the prosthesis are configured and deployed in the same manner as described previously. Following placement within the contralateral iliac as described above, the restraint 100 can be retracted from the proximal end of the deployment system, releasing the contralateral limb and allowing it to expand. The deployment system including the restraint 100 is then removed from the single access port.


Alternatively, a water soluble adhesive can be utilized to encapsulate the compressed contralateral limb 70. Following retraction of the outer sheath 50 and positioning within the contralateral iliac 26, exposure to blood causes the dissolvable restraint material to dissolve, eventually permitting the contralateral limb 70 to expand to its implanted diameter. A wide variety of biomaterials which are absorbable in an aqueous environment over different time intervals are known, including a variety of compounds in the polyglycolic acid family, as will be understood by those of skill in the art. In this embodiment, the bioadhesive or other bioabsorbable restraint compound mast permit sufficient time for the contralateral limb 70 to be properly positioned within the contralateral iliac 26 before releasing the contralateral limb 70 as will be appreciated by those of skill in the art.


In another variation of the single vessel deployment system of the present invention, a tubular sheath 102 is used to restrain the contralateral limb as shown in FIGS. 11 and 12. Before or after the main body 74 and ipsilateral limb 72 of the graft 76 are deployed as described above, the contralateral limb 70 is deployed by proximally retracting a release wire 103. The proximal movement of the release wire 103 causes the contralateral sheath 102 to advance inferiorly into the contralateral iliac, thereby releasing the self-expandable wire cage within the contralateral limb as depicted in FIG. 12.


In the embodiment of FIGS. 11 and 12, the release wire 103 comprises a proximal ipsilateral segment 104 and a distal, contralateral segment 106. Ipsilateral segment 104 and contralateral segment 106 are joined at an apex 108. Apex 108 may be a bend in the release wire 103, or a joint such as for securing two separate segments together. The release wire 103, particularly in the region of the apex 108, must have sufficient structural integrity that proximal retraction of the proximal end of release wire 103 will cause movement of the contralateral segment 106 in the inferior direction (down the contralateral iliac away from the aorta). The contralateral iliac segment 106 is secured at its distal end to the tubular sheath 102. The release wire 103 may be formed from any of a variety of materials and dimensions as will be apparent in view of the disclosure herein. In one embodiment a circular cross-section, solid wire having a diameter in the range of about 0.020 inches to about 0.030 inches may be used.


Following proximal retraction of the release wire 103 to deploy the contralateral iliac segment 70, the release wire 103 is advanced distally, thereby drawing the tubular sheath 102 in a superior direction through the expanded contralateral limb of the graft and towards the aorta. A medially-directed bias exerted by apex 108 urges the tubular sheath 102 in the direction of the ipsilateral iliac. Once the sheath 102 is positioned at the opening to the ipsilateral iliac, the release wire 103 may be withdrawn. Alternatively, the release wire 103 may simply be proximally withdrawn, drawing the tubular sheath 102 through the contralateral graft segment 70 as will be appreciated by those of skill in the art in view of the disclosure herein.


In a variation of this design, a wire without an apex, which is fastened to the distal tip of the sheath 102, may be retracted, thereby pulling the contralateral limb sheath from outside in, through and off of the contralateral limb and out through the lumen.


In a further embodiment of the present invention, the contralateral iliac segment 70 is restrained in its insertion profile by a peelable sheath 110. The peelable sheath 110 can be removed to release the contralateral iliac segment 70 by proximal retraction, preferably into the catheter. The use of one embodiment of a peelable sheath for restraining and deploying contralateral iliac segment 70 is illustrated in FIGS. 13 through 17.


Referring to FIG. 13, there is illustrated a deployment device positioned within an aneurysm 24 in the aorta 22 at the bifurcation of the ipsilateral iliac 20 and contralateral iliac 26. The main body 74 of the graft has already been deployed within the aorta 22 in accordance with techniques previously disclosed. In this embodiment, as explained below, the graft tube 33 constrained the main body 74 of the graft, the ipsilateral limb cover 44 constrains the ipsilateral limb 72 and a peelable sheath 110 constrains the contralateral iliac segment. As shown, in FIG. 13, the graft tube 33, the ipsilateral limb cover 44 and the peelable sheath 110 are arranged in a Y-configuration.


Following retraction of the outer sheath 40 in a proximal direction to release the constrained contralateral iliac segment 70 for positioning within the contralateral iliac 26, (as illustrated in FIG. 13), the outer sheath 40 is distally advanced to the bifurcation as illustrated in FIG. 14. At this point, the system is prepared for release of the peelable sheath 110.


Referring to FIG. 13A, a peelable sheath 110 is disclosed for releasably restraining the contralateral iliac segment 70. The peelable sheath 110 comprises a tubular body 112 having a proximal (superior) end 114 and a distal (inferior) end 116. The peelable sheath 110 is secured to a contralateral graft actuator 60 such as a release wire 103. The release wire 103 in the illustrated embodiment is secured by way of a joint 120 to the proximal end 114 of the peelable sheath 110, and extends through the middle core 40 to the proximal end of the catheter.


The proximal end 114 of sheath 110 is preferably provided with a leader 128 of sheath material to facilitate positioning the joint 126 on the ipsilateral limb side of the bifurcation. Preferably, the peelable sheath 110 is provided with a peel start point 130 such as a slit, perforation, V-shaped cut, or otherwise as will be apparent to those of skill in the art in view of the disclosure herein. The peelable sheath 110 may further be provided with a perforation line, crease or other tear facilitating modification extending axially there along to facilitate predictable tearing of the material.


The peelable sheath 110 may be made from any of a variety of thin, tearable materials as will be apparent to those of skill in the art in view of the disclosure herein. Preferably, the material exhibits sufficient strength that it will restrain the self expandable contralateral iliac segment 70 while at the same time maintaining a low cross sectional profile and also permitting tearing to occur with a minimal amount of traction required on the release wire 103. In one embodiment, the peelable sheath 110 comprises a PTFE tube having a wall thickness of about 0.011″, an outside diameter of about 0.196″ and a length from the peel start point 130 to the distal end 116 of about 5.0 cm. The overall length from the joint 120 to the distal end 116 is about 6.0 cm. Specific dimensions may be optimized for any particular device as will be understood in the art. Other thin wall tearable materials may also be used, such as PET, HDPE, or PE.


Referring to FIG. 14, the distal end of the outer sheath 40 provides a fulcrum for minimizing injury to the adjacent tissue as proximal traction is applied to the release wire 103. Proximal retraction of the release wire 103 pulls the peelable sheath 110 in a proximal (superior) direction, around the bifurcation and down into the tubular outer sheath 40. As illustrated in FIG. 15, retraction of the pull wire 103 slides the tubular body 112 superiorly along the contralateral iliac segment 70 such that the contralateral iliac segment 70 is released from the inferior end first. Further proximal retraction of the release wire 103 causes the peelable sheath 110 to tear or split thereby permitting complete retraction of the peelable sheath 110 from the contralateral iliac segment 70 as illustrated in FIG. 16. Following deployment of the contralateral iliac segment 70, the middle core 40 and/or a separate ipsilateral limb cover 44, where utilized, may be proximally retracted to deploy the ipsilateral limb 72.


As will be apparent in view of the disclosure herein, the release wire 103 may extend through the outer core 50 or the middle core 40, through a dedicated lumen in the wall of either, or outside of the catheter as may be desired for particular product designs.


The release wire 103 may be attached to the peelable sheath 110 at either the proximal end 114 or the distal end 116. In the illustrated embodiment, the release wire 103 is attached to the leader 128 at joint 126. Joint 126 comprises a barbed metal cylinder for grabbing the PTFE. Any of a variety of alternate structures or materials for fastening the release wire 103 to the peelable sheath 110 may alternatively be utilized provided the joint 126 has sufficient integrity to pull the peelable sheath 110 and permit splitting of the sheath to release the contralateral iliac segment 170.


Although the peelable sheath 110 in the foregoing embodiment was disclosed as restraining the contralateral iliac limb, the peelable sheath may be used on any of the contralateral, ipsilateral, or main branch portions of the graft. For example, in one embodiment, the main body portion of the graft is restrained within the graft tube 33, and each of the contralateral and ipsilateral iliac graft branches are restrained by a peelable sheath. In an alternate embodiment, all three portions of the graft are restrained by peelable sheaths. As a further alternative, the main graft body and the contralateral iliac limb portions of the graft are restrained by first and second peelable sheaths and the ipsilateral portion of the graft is restrained by a proximally retractable sleeve as has been disclosed previously herein. The desirability of any of the foregoing combinations will be apparent to one of ordinary skill in the art in view of the design parameters for a particular catheter built in accordance with the present invention.


Referring to FIG. 18, an embodiment of a self-expanding bifurcated prosthesis in accordance with the present invention is shown having a polymeric sleeve 80 and a tubular wire support 90. Many of the features of the self-expandable graft of the present invention are disclosed in co-pending U.S. patent application Ser. No. 09/100,481 entitled “Self Expanding Bifurcated Endovascular Prosthesis,” filed Jun. 19, 1998, and copending U.S. patent application Ser. No. 09/210,280, entitled “Endoluminal Vascular Prosthesis,” filed Dec. 11, 1998, the disclosures of which are incorporated in their entirety herein by reference.


The polymeric sleeve 80 may be situated concentrically outside of the tubular wire support 90. However, other embodiments may include a sleeve situated instead concentrically inside the wire support or on both of the inside and the outside of the wire support. Alternatively, the wire support may be embedded within a polymeric matrix that makes up the sleeve. Regardless of whether the sleeve is inside or outside the wire support, the sleeve may be attached to the wire support by any of a variety of means, including laser bonding, adhesives, clips, sutures, dipping or spraying or others, depending upon the composition of the sleeve and overall graft design.


The polymeric sleeve may be formed from any of a variety of synthetic polymeric materials, or combinations thereof, including PTFE, PE, PET, Urethane, Dacron, nylon, polyester or woven textiles. Preferably, the sleeve material exhibits relatively low inherent elasticity, or low elasticity out to the intended enlarged diameter of the wire cage. The sleeve material preferably has a thin profile, such as no larger than about 0.002 inches to about 0.005 inches.


In one embodiment of the invention, the material of the sleeve is sufficiently porous to permit in-growth of endothelial cells, thereby providing more secure anchorage of the prosthesis and potentially reducing flow resistance, shear forces, and leakage of blood around the prosthesis. Porosity in polymeric sleeve materials may be estimated by measuring water permeability as a function of hydrostatic pressure, which will preferably range from about 3 to 6 psi.


The porosity characteristics of the polymeric sleeve may be either homogeneous throughout the axial length of the prosthesis, or may vary according to the axial position along the prosthesis. For example, at least a distal portion and right and left proximal portions of the prosthesis will seat against the native vessel walls, proximally and distally of the aneurysm. In at least these proximal and distal portions, the prosthesis preferably encourages endothelial growth, or, at least, permits endothelial growth to infiltrate portions of the prosthesis in order to enhance anchoring and minimize leakage. For the central portion of the prosthesis, which spans the aneurysm, anchoring is less of an issue. Instead, minimizing blood flow through the prosthesis wall becomes a primary objective. Thus, in a central zone of the prosthesis, the polymeric sleeve may either be nonporous, or provided with pores that minimize or prevent leakage.


A multi-zoned prosthesis may also be provided in accordance with the present invention by positioning a tubular sleeve on a central portion of the prosthesis, such that it spans the aneurysm to be treated, but leaving the wire support in the proximal and distal attachment zones exposed. In this embodiment, the exposed wires are positioned in contact with the vessel wall both proximally and distally of the aneurysm, such that the wire, over time, becomes embedded in cell growth on the interior surface of the vessel wall.


In one embodiment of the prosthesis, the sleeve and/or the wire support is stepped or tapered, having a relatively larger expanded diameter at the proximal end compared to the distal ends. The tapered design may allow the prosthesis to conform better to the natural decreasing distal cross section of the aorta and iliac arteries to reduce the risk of leakage and graft migration and potentially create better flow dynamics.


Referring to FIG. 18, the tubular wire support comprises a main body 92 for traversing the aorta and a first, ipsilateral iliac limb 94, and a secondary component for extending into the second, contralateral iliac limb 96. The contralateral limb cage may be constructed from a memory alloy wire such as Nitinol as has been discussed. The main body and ipsilateral limb structures may be constructed from a non-memory alloy wire.


Referring to FIG. 19, one embodiment of the prosthesis 76 is shown, wherein the limbs expand laterally away from one another due to an expansion spring 120, comprising an apex and first and second leg portions. The leg portions are connected to the wire cage 90 of both the ipsilateral and contralateral limbs at connection point 122. The apex 124 of the expansion spring 120 is located at the bifurcation.


With reference to FIG. 20, one embodiment of the wire structure for the primary wire support components is shown, wherein the wire cage is formed from one or more lengths of wire into a series of straight struts separated by apexes into a zig-zag pattern. The contralateral wire cage may also be constructed from one or more zig-zag wires as illustrated. When a tubular wire cage is formed by rolling the formed wire about an axis, the connectors 98 collectively produce a generally axially extending backbone that adds axial strength to the prosthesis. The wire support is formed in a plurality of discrete segments, connected together and oriented about a common axis. A connector wire 98 connects adjacent segments together. Opposing wire apexes of adjacent segments can be connected in any of a variety of ways including circumferentially extending sutures, solder joints, wire loops and any of a variety of interlocking relationships, such as those disclosed in copending U.S. patent application Ser. No. 09/210,280, filed Dec. 11, 1998, entitled “Endoluminal Vascular Prosthesis”, the disclosure of which is incorporated in its entirety herein by reference. The contralateral limb cage may be joined to the main body and ipsilateral limb component by similar sutures, solder joints, wire loops and/or interlocking relationships.


The segmented configuration of the tubular wire supports facilitates a great deal of flexibility. Each segment, though joined to adjacent segments, may be independently engineered to yield desired parameters. Each segment may range in axial length from about 0.3 to about 5 cm. Generally, the shorter their length the greater the radial strength. The primary component of an endoluminal prosthesis may include from about 2 to about 50 segments, preferably from about 8 to about 16 segments.


In general, each of the components of the tubular wire support can be varied considerably in diameter, length, and expansion coefficient, depending upon the intended application. For implantation within a typical adult, the aorta trunk portion will have a length within the range of from about 5 cm to about 12 cm, and, typically within the range of from about 9 cm to about 10 cm. The unconstrained outside expanded diameter this portion will typically be within the range of from about 20 mm to about 40 mm. The unconstrained expanded outside diameter of this portion can be constant or substantially constant throughout its length, or can be tapered from a relatively larger diameter at the proximal end to a relatively smaller diameter at the bifurcation. In general, the diameter of the distal end will be on the order of no more than about 95% and, preferably, no more than about 85% of the diameter of the proximal end of the aortic trunk portion.


Different zones of the prosthesis can be provided with differing expanded diameters. Further, the different zones can be provided with a different radial expansion force, such as ranging from about 2 lbs. to about 8 lbs. In one embodiment, the proximal zone is provided with a greater radial force than the central zone and/or distal zone. A greater radial force can be provided in any of a variety of manners, such as through the use of additional wire bends and wall sections. Alternatively, additional spring force can be achieved through the use of a heavier gauge wire. Increased radial force and expansion diameter in the proximal and distal regions relative to a central region can be achieved by tightening a circumferential suture such that the central region is retained under compression even in the expanded configuration. By omitting a circumferential suture at the proximal end and/or distal ends of the prosthesis, the proximal end and distal ends will flair radially outwardly to a fully expanded configuration.


The wire for the main body and ipsilateral limb cages may be made from any of a variety of different alloys, such as elgiloy or MP35N, or other alloys which include nickel, titanium, tantalum, or stainless steel, high Co—Cr alloys or other temperature sensitive materials. For example, an alloy comprising Ni 15%, Co 40%, Cr 20%, Mo 7% and balance Fe may be used. The tensile strength of suitable wire is generally above about 300 K psi and often between about 300 and about 340 K psi for many embodiments. In one embodiment, a Chromium-Nickel-Molybdenum alloy such as that marketed under the name Conichrom (Fort Wayne Metals, Indiana) has a tensile strength ranging from 300 to 320 K psi, elongation of 3.5-4.0% and breaking load at approximately 80 lbs. to 70 lbs. As mentioned above, at least the contralateral limb cage may be constructed from a memory alloy such as Nitinol, which will remain in a small profile until heated to the memory alloy's transition temperature, at which point the contralateral limb cage expands to a predisposed shape. In any case, both the memory and non-memory alloy wires may be treated with a plasma coating and be provided with or without additional coatings such as PTFE, Teflon, Perlyne, drugs, and others as will be understood by those of skill in the art.


In addition to segment length and bend configuration, another determinant of radial strength is wire gauge. The radial strength, measured at 50% of the collapsed profile, preferably ranges from about 2 lb. to 8 lb., and generally from about 4 lb. to about 5 lb. or more. Preferred wire diameters in accordance with the present invention range from about 0.004 inches to about 0.020 inches. More preferably, the wire diameters range from about 0.006 inches to about 0.018 inches. In general, the greater the wire diameter, the greater the radial strength for a given wire layout. Thus, the wire gauge can be varied depending upon the application of the finished graft, in combination with/or separate from variation in other design parameters.


A wire diameter of approximately 0.018 inches may be useful in the aorta trunk portion of a graft, while a smaller diameter such as 0.006 inches might be useful for the iliac limb segment.


In one embodiment of the present invention, the wire diameter is tapered throughout from the proximal to distal ends. Alternatively, the wire diameter may be tapered incremental or stepped down, or stepped up, depending on the radial strength requirements of each particular clinical application. In general, in the tapered or stepped wire embodiments, the diameter of the wire in the iliac branches is no more than about 80%, preferably no more than about 50%, and optimally no more than about 35% of the diameter of the wire in the aortic trunk. This permits increased flexibility of the graft in the region of the iliac branches, which has been determined by the present inventors to be clinically desirable.


Additional details of the wire cage layout and construction can be found in co-pending U.S. patent application Ser. No. 09/034,689 entitled “Endoluminal Vascular Prosthesis,” filed Mar. 4, 1998, the disclosure of which is incorporated in its entirety herein by reference.


The collapsed prosthesis in accordance with the present invention has a diameter in the range of about 2 to about 10 mm. Preferably, the maximum diameter of the collapsed prosthesis is in the range of about 3 to 6 mm (12 to 18 French). More particularly, the delivery catheter including the prosthesis will be 19 F, 16 F, 14 F, or smaller. After deployment, the expanded endoluminal vascular prosthesis radially self-expands to a diameter anywhere in the range of from about 20 to about 40 mm, corresponding to expansion ratios of about 1:2 to 1:20. In a preferred embodiment, the expansion ratios range from about 1:4 to 1:8, more preferably from about 1:4 to 1:6.


While a number of variations of the invention have been described in detail, other modifications and methods of use will be readily apparent to those of skill in the art. Accordingly, it should be understood that various applications, modifications and substitutions may be made of equivalents without departing from the spirit of the invention or the scope of the claims.

Claims
  • 1. A graft deployment system, comprising: an elongate, flexible catheter body, having a proximal end and a distal end;a main vessel graft restraint for restraining a main vessel portion of a graft;a first branch vessel graft restraint for restraining a first branch vessel portion of the graft; anda second branch vessel graft restraint for restraining a second branch vessel portion of the graft;wherein: the main vessel graft restraint, the first branch vessel graft restraint, and the second branch vessel restraint are arranged in a Y-configuration that is advanced through a first puncture site in a patient's vasculature; andthe deployment system is configured such that the main vessel graft restraint, the first branch vessel graft restraint, and the second branch vessel graft restraint are connected to a portion of said graft deployment system to be withdrawn with the graft deployment system through the first puncture site after deployment of the main vessel graft portion of the graft, the first branch vessel portion of the graft, and the second branch vessel portion of the graft.
  • 2. The deployment system of claim 1, wherein the second vessel graft restraint comprises a water-soluble bioadhesive.
  • 3. The deployment system of claim 2, wherein the water-soluble bioadhesive comprises compounds in the polyglycolic acid family.
  • 4. The deployment system of claim 1, wherein the main vessel graft restraint is perforated along at least a portion of a length thereof.
  • 5. The deployment system of claim 1, wherein at least one of the main vessel graft restraint, the first branch vessel graft restraint, and the second branch vessel graft restraint is perforated along at least a portion of a length thereof.
  • 6. The deployment system of claim 1, wherein said graft is a bifurcated graft.
  • 7. The deployment system of claim 1, further comprising an outer sheath, an inner core that is axially moveable with respect to the outer sheath, and a distal tip coupled to the inner core.
  • 8. The deployment system of claim 1, wherein the first and second branch vessel graft restraints are separate restraints.
  • 9. The deployment system of claim 1, wherein the graft comprises a self-expanding support structure positioned inside the main vessel portion of the graft, the first branch vessel portion of the graft, and the second branch vessel portion of the graft.
  • 10. The deployment system of claim 1, wherein a length of the first branch vessel portion of the graft is approximately the same as a length of the second branch vessel portion of the graft.
  • 11. The deployment system of claim 1, wherein the deployment system is configured such that the first branch vessel graft restraint is configured to be removed from the first branch vessel portion of the graft after the first branch vessel portion of the graft is inserted into the first branch vessel, and the second branch vessel graft restraint is configured to be removed from the second branch vessel portion of the graft after the second branch vessel portion of the graft is inserted into the second branch vessel.
  • 12. The deployment system of claim 1, wherein the first branch vessel graft restraint covers only the first branch vessel portion of the graft and the second branch vessel graft restraint restrains only the second branch vessel portion of the graft.
  • 13. The deployment system of claim 1, wherein the first puncture site is in a first branch vessel, the first branch vessel portion of the graft is deployable in the first branch vessel by removal of the first branch vessel graft restraint, and the second branch vessel portion of the graft is deployable in a second branch vessel by removal of the second branch vessel graft restraint, which restrains only the second branch vessel portion of the graft.
  • 14. The deployment system of claim 1, wherein a portion of the graft deployment system containing the graft is configured to be introduced through the first puncture site and, after deployment of the main vessel graft portion of the graft, the first branch vessel portion of the graft, and the second branch vessel portion of the graft have been deployed, the portion of the graft deployment system that had contained the graft prior to deployment is withdrawn from the first puncture site.
  • 15. A graft deployment system, comprising: an elongate, flexible catheter body, having a proximal end and a distal end and comprising an outer sheath and an inner core that is axially moveable with respect to the outer sheath and a distal tip positioned adjacent the distal end of the catheter body;a graft having a main vessel portion, a first branch vessel portion, and a second branch vessel portion; anda restraint system configured to restrain the main vessel portion, the first branch vessel portion, and the second branch vessel portion;wherein: the deployment system is configured to be inserted through a first puncture site in a first branch vessel of a patient's vasculature;the restraint system comprises a second branch vessel restraint configured to restrain only the second branch vessel portion that is positionable in the second branch vessel; andthe restraint system is configured to be completely withdrawn through the first puncture site in the first branch vessel after deployment of the main vessel portion, the first branch vessel portion, and the second branch vessel portion.
  • 16. The deployment system of claim 15, wherein the graft is a bifurcated graft.
  • 17. The deployment system of claim 15, wherein the restraint system comprises at least one peelable sheath.
  • 18. The deployment system of claim 15, wherein the restraint system comprises at least one perforated sheath.
  • 19. The deployment system of claim 15, comprising a peelable tubular sheath to restrain the main vessel portion of the graft.
  • 20. The deployment system of claim 15, comprising a first peelable tubular sheath to restrain the main vessel portion of the graft and a second peelable tubular sheath to restrain at least the second branch vessel portion of the graft.
  • 21. The deployment system of claim 15, wherein at least the portion of the restraint system restraining the main vessel portion and the second branch vessel portion of the graft is perforated.
  • 22. The deployment system of claim 15, wherein at least a portion of the restraint system is coupled to the inner core.
  • 23. The deployment system of claim 15, wherein the distal tip is coupled to the inner core.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 10/690,227, filed Oct. 21, 2003, now U.S. Pat. No. 7,691,135, which is a continuation of U.S. patent application Ser. No. 09/795,993, filed Feb. 28, 2001, now U.S. Pat. No. 6,663,665, which is a divisional of U.S. patent application Ser. No. 09/266,661, filed on Mar. 11, 1999, now U.S. pat. No. 6,261,316.

US Referenced Citations (482)
Number Name Date Kind
2127903 Bowen Aug 1938 A
2437542 Krippendorf Mar 1948 A
2845959 Sidebotham Aug 1958 A
2990605 Demsyk Jul 1961 A
3029819 Starks Apr 1962 A
3096560 Liebig Jul 1963 A
3805301 Liebig Apr 1974 A
4497074 Rey et al. Feb 1985 A
4501263 Harbuck Feb 1985 A
4503568 Madras Mar 1985 A
4580568 Gianturco Apr 1986 A
4592754 Gupte et al. Jun 1986 A
4617932 Kornberg Oct 1986 A
4756307 Crowninshield Jul 1988 A
4800882 Gianturco Jan 1989 A
4816028 Kapadia et al. Mar 1989 A
4840940 Sottiurai Jun 1989 A
4856516 Hillstead Aug 1989 A
4878906 Lindemann et al. Nov 1989 A
4907336 Gianturco Mar 1990 A
4922905 Strecker May 1990 A
4981478 Evard et al. Jan 1991 A
4981947 Tomagou et al. Jan 1991 A
4994071 MacGregor Feb 1991 A
5019090 Pinchuk May 1991 A
5026377 Burton et al. Jun 1991 A
5035706 Giantureo et al. Jul 1991 A
5064435 Porter Nov 1991 A
5078726 Kreamer Jan 1992 A
5104399 Lazarus Apr 1992 A
5108424 Hoffman, Jr. et al. Apr 1992 A
5116349 Aranyi May 1992 A
5123917 Lee Jun 1992 A
5133732 Wiktor Jul 1992 A
5135536 Hillstead Aug 1992 A
5156619 Ehrenfeld Oct 1992 A
5178634 Martinez Jan 1993 A
5197976 Herweck et al. Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5211658 Clouse May 1993 A
5246452 Sinnott Sep 1993 A
5256141 Gencheff et al. Oct 1993 A
5275622 Lazarus et al. Jan 1994 A
5282824 Gianturco Feb 1994 A
5282860 Matsuno et al. Feb 1994 A
5304200 Spaulding Apr 1994 A
5314444 Gianturco May 1994 A
5314472 Fontaine May 1994 A
5316023 Palmaz et al. May 1994 A
5320602 Karpiel Jun 1994 A
5330500 Song Jul 1994 A
5342387 Summers Aug 1994 A
5354308 Simon et al. Oct 1994 A
5360443 Barone et al. Nov 1994 A
5366504 Andersen et al. Nov 1994 A
5370683 Fontaine Dec 1994 A
5387235 Chuter Feb 1995 A
5397355 Marin et al. Mar 1995 A
5403341 Solar Apr 1995 A
5405377 Cragg Apr 1995 A
5405378 Strecker Apr 1995 A
5415664 Pinchuk May 1995 A
5423886 Arru et al. Jun 1995 A
5425765 Tiefenbrun et al. Jun 1995 A
5443477 Marin et al. Aug 1995 A
5443498 Fontaine Aug 1995 A
5443500 Sigwart Aug 1995 A
5453090 Martinez et al. Sep 1995 A
5456713 Chuter Oct 1995 A
5458615 Klemm et al. Oct 1995 A
5462530 Jang Oct 1995 A
5464449 Ryan et al. Nov 1995 A
5464450 Buscemi Nov 1995 A
5484444 Braunschweiler et al. Jan 1996 A
5489295 Piplani et al. Feb 1996 A
5496365 Sgro Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5507768 Lau et al. Apr 1996 A
5507769 Marin et al. Apr 1996 A
5507771 Gianturco Apr 1996 A
5522880 Barone et al. Jun 1996 A
5522881 Lentz Jun 1996 A
5522883 Slater et al. Jun 1996 A
5545211 An et al. Aug 1996 A
5549635 Solar Aug 1996 A
5554118 Jang Sep 1996 A
5554181 Das Sep 1996 A
5562697 Christiansen Oct 1996 A
5562726 Chuter Oct 1996 A
5562728 Lazarus et al. Oct 1996 A
5571169 Plaia et al. Nov 1996 A
5571172 Chin Nov 1996 A
5571173 Parodi Nov 1996 A
5575816 Rudnick et al. Nov 1996 A
5575818 Pinchuk Nov 1996 A
5578071 Parodi Nov 1996 A
5578072 Barone et al. Nov 1996 A
5591197 Orth et al. Jan 1997 A
5591198 Boyle et al. Jan 1997 A
5591226 Trerotola et al. Jan 1997 A
5591228 Edoga Jan 1997 A
5591229 Parodi Jan 1997 A
5591230 Horn et al. Jan 1997 A
5593417 Rhodes Jan 1997 A
5599305 Hermann et al. Feb 1997 A
5604435 Foo et al. Feb 1997 A
5607445 Summers Mar 1997 A
5609625 Piplani et al. Mar 1997 A
5609627 Goicoechea et al. Mar 1997 A
5609628 Keranen Mar 1997 A
5628783 Quiachon et al. May 1997 A
5628786 Banas et al. May 1997 A
5628788 Pinchuk May 1997 A
5630829 Lauterjung May 1997 A
5630830 Verbeek May 1997 A
5632763 Glastra May 1997 A
5632772 Alcime et al. May 1997 A
5639278 Dereume et al. Jun 1997 A
5641373 Shannon et al. Jun 1997 A
5643171 Bradshaw et al. Jul 1997 A
5643278 Wijay Jul 1997 A
5643339 Kavteladze et al. Jul 1997 A
5647857 Anderson et al. Jul 1997 A
5649952 Lam Jul 1997 A
5651174 Schwartz et al. Jul 1997 A
5653727 Wiktor Aug 1997 A
5653743 Martin Aug 1997 A
5653746 Schmitt Aug 1997 A
5653747 Dereume Aug 1997 A
5653748 Strecker Aug 1997 A
5662580 Bradshaw et al. Sep 1997 A
5662614 Edoga Sep 1997 A
5662675 Polanskyj Stockert et al. Sep 1997 A
5662700 Lazarus Sep 1997 A
5662701 Plaia et al. Sep 1997 A
5662702 Keranen Sep 1997 A
5662703 Yurek et al. Sep 1997 A
5665115 Cragg Sep 1997 A
5665117 Rhodes Sep 1997 A
5669880 Solar Sep 1997 A
5669924 Shaknovich Sep 1997 A
5669934 Sawyer Sep 1997 A
5674241 Bley et al. Oct 1997 A
5674276 Andersen et al. Oct 1997 A
5676685 Razavi Oct 1997 A
5676696 Marcade Oct 1997 A
5676697 McDonald Oct 1997 A
5679400 Tuch Oct 1997 A
5681345 Euteneuer Oct 1997 A
5681346 Orth et al. Oct 1997 A
5683448 Cragg Nov 1997 A
5683449 Marcade Nov 1997 A
5683450 Goicoechea et al. Nov 1997 A
5683451 Lenker et al. Nov 1997 A
5683452 Barone et al. Nov 1997 A
5683453 Palmaz Nov 1997 A
5690642 Osborne et al. Nov 1997 A
5690643 Wijay Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5693066 Rupp et al. Dec 1997 A
5693084 Chuter Dec 1997 A
5693086 Goicoechea et al. Dec 1997 A
5693087 Parodi Dec 1997 A
5693088 Lazarus Dec 1997 A
5695516 Fischell et al. Dec 1997 A
5695517 Marin et al. Dec 1997 A
5697948 Marin et al. Dec 1997 A
5709703 Lukic et al. Jan 1998 A
5713917 Leonhardt Feb 1998 A
5716365 Goicoechea et al. Feb 1998 A
5716393 Lindenberg et al. Feb 1998 A
5718724 Goicoechea et al. Feb 1998 A
5718973 Lewis et al. Feb 1998 A
5720735 Dorros Feb 1998 A
5720776 Chuter et al. Feb 1998 A
5723004 Dereume et al. Mar 1998 A
5733267 Del Toro Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5746766 Edoga May 1998 A
5749880 Banas et al. May 1998 A
5755770 Ravenscroft May 1998 A
5755771 Penn et al. May 1998 A
5755777 Chuter May 1998 A
5765682 Bley et al. Jun 1998 A
5766203 Imran et al. Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5769885 Quiachon et al. Jun 1998 A
5769887 Brown et al. Jun 1998 A
5782855 Lau et al. Jul 1998 A
5782909 Quiachon et al. Jul 1998 A
5800456 Maeda et al. Sep 1998 A
5800508 Goicoechea et al. Sep 1998 A
5800514 Nunez et al. Sep 1998 A
5800526 Anderson et al. Sep 1998 A
5800540 Chin Sep 1998 A
5810836 Hussein et al. Sep 1998 A
5817100 Igaki Oct 1998 A
5824037 Fogarty et al. Oct 1998 A
5824039 Piplani et al. Oct 1998 A
5824040 Cox et al. Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5843160 Rhodes Dec 1998 A
5843162 Inoue Dec 1998 A
5843164 Frantzen et al. Dec 1998 A
5843167 Dwyer et al. Dec 1998 A
5851228 Pinheiro Dec 1998 A
5855599 Wan Jan 1999 A
5860998 Robinson et al. Jan 1999 A
5865844 Plaia et al. Feb 1999 A
5867432 Toda Feb 1999 A
5868783 Tower Feb 1999 A
5871536 Lazarus Feb 1999 A
5879321 Hill Mar 1999 A
5879366 Shaw et al. Mar 1999 A
5891193 Robinson et al. Apr 1999 A
5893868 Hanson et al. Apr 1999 A
5893887 Jayaraman Apr 1999 A
5902334 Dwyer et al. May 1999 A
5906640 Penn et al. May 1999 A
5906641 Thompson et al. May 1999 A
5916263 Goicoechea et al. Jun 1999 A
5919225 Lau et al. Jul 1999 A
5925075 Myers et al. Jul 1999 A
5928279 Shannon et al. Jul 1999 A
5935161 Robinson et al. Aug 1999 A
5938696 Goicoechea et al. Aug 1999 A
5948018 Dereume et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5957973 Quiachon et al. Sep 1999 A
5961546 Robinson et al. Oct 1999 A
5961548 Shmulewitz Oct 1999 A
6001125 Golds et al. Dec 1999 A
6004347 McNamara et al. Dec 1999 A
6004348 Banas et al. Dec 1999 A
6017363 Hojeibane Jan 2000 A
6019785 Strecker Feb 2000 A
6027508 Ren et al. Feb 2000 A
6027779 Campbell et al. Feb 2000 A
6027811 Campbell et al. Feb 2000 A
6030415 Chuter Feb 2000 A
6039749 Marin et al. Mar 2000 A
6039755 Edwin et al. Mar 2000 A
6039758 Quiachon et al. Mar 2000 A
6045557 White et al. Apr 2000 A
6051020 Goicoechea et al. Apr 2000 A
6053940 Wijay Apr 2000 A
6056722 Jayaraman May 2000 A
6059813 Vrba et al. May 2000 A
6063092 Shin May 2000 A
6063113 Kavteladze et al. May 2000 A
6070589 Keith et al. Jun 2000 A
6074398 Leschinsky Jun 2000 A
6077296 Shokoohi et al. Jun 2000 A
6077297 Robinson et al. Jun 2000 A
6086611 Duffy et al. Jul 2000 A
6090128 Douglas Jul 2000 A
6090135 Plaia et al. Jul 2000 A
6093194 Mikus et al. Jul 2000 A
6093203 Uflacker Jul 2000 A
6096027 Layne Aug 2000 A
6106548 Roubin et al. Aug 2000 A
6113607 Lau et al. Sep 2000 A
6117167 Goicoechea et al. Sep 2000 A
6123722 Fogarty et al. Sep 2000 A
6123723 Kónya et al. Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6129756 Kugler et al. Oct 2000 A
6143016 Bleam et al. Nov 2000 A
6146389 Geitz Nov 2000 A
6152944 Holman et al. Nov 2000 A
6162237 Chan Dec 2000 A
6165214 Lazarus Dec 2000 A
6168610 Marin et al. Jan 2001 B1
6183481 Lee et al. Feb 2001 B1
6183509 Dibie Feb 2001 B1
6187036 Shaolian et al. Feb 2001 B1
6192944 Greenhalgh Feb 2001 B1
6197049 Shaolian et al. Mar 2001 B1
6203735 Edwin et al. Mar 2001 B1
6221081 Mikus et al. Apr 2001 B1
6221102 Baker et al. Apr 2001 B1
6224627 Armstrong et al. May 2001 B1
6231563 White et al. May 2001 B1
6238410 Vrba et al. May 2001 B1
6254609 Vrba et al. Jul 2001 B1
6254628 Wallace et al. Jul 2001 B1
6261316 Shaolian et al. Jul 2001 B1
6273909 Kugler et al. Aug 2001 B1
6280466 Kugler et al. Aug 2001 B1
6280467 Leonhardt Aug 2001 B1
6283991 Cox et al. Sep 2001 B1
6287315 Wijeratne et al. Sep 2001 B1
6287329 Duerig et al. Sep 2001 B1
6312406 Jayaraman Nov 2001 B1
6331184 Abrams Dec 2001 B1
6331190 Shokoohi et al. Dec 2001 B1
6348066 Pinchuk et al. Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6352553 van der Burg et al. Mar 2002 B1
6352561 Leopold et al. Mar 2002 B1
6355060 Lenker et al. Mar 2002 B1
6361557 Gittings et al. Mar 2002 B1
6361559 Houser et al. Mar 2002 B1
6361637 Martin et al. Mar 2002 B2
6380457 Yurek et al. Apr 2002 B1
6395017 Dwyer et al. May 2002 B1
6395018 Castaneda May 2002 B1
6395019 Chobotov May 2002 B2
6398807 Chouinard et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6409757 Trout, III et al. Jun 2002 B1
6416474 Penner et al. Jul 2002 B1
6416529 Holman et al. Jul 2002 B1
6416542 Marcade et al. Jul 2002 B1
6432130 Hanson Aug 2002 B1
6432131 Ravenscroft Aug 2002 B1
6432134 Anson et al. Aug 2002 B1
6440161 Madrid Aug 2002 B1
6447540 Fontaine et al. Sep 2002 B1
6464721 Marcade et al. Oct 2002 B1
6475166 Escano Nov 2002 B1
6475170 Doron et al. Nov 2002 B1
6482211 Choi Nov 2002 B1
6485513 Fan Nov 2002 B1
6491719 Fogarty et al. Dec 2002 B1
6500202 Shaolian et al. Dec 2002 B1
6508833 Pavcnik et al. Jan 2003 B2
6508835 Shaolian et al. Jan 2003 B1
6511325 Lalka et al. Jan 2003 B1
6514281 Blaeser et al. Feb 2003 B1
6517569 Mikus et al. Feb 2003 B2
6517572 Kugler et al. Feb 2003 B2
6517573 Pollock et al. Feb 2003 B1
6520988 Colombo et al. Feb 2003 B1
6524335 Hartley et al. Feb 2003 B1
6533811 Ryan et al. Mar 2003 B1
6544278 Vrba et al. Apr 2003 B1
6551350 Thornton et al. Apr 2003 B1
6558396 Inoue May 2003 B1
6562063 Euteneuer et al. May 2003 B1
6565596 White et al. May 2003 B1
6565597 Fearnot et al. May 2003 B1
RE38146 Palmaz et al. Jun 2003 E
6572645 Leonhardt Jun 2003 B2
6576005 Geitz Jun 2003 B1
6576009 Ryan et al. Jun 2003 B2
6582460 Cryer Jun 2003 B1
6585758 Chouinard et al. Jul 2003 B1
6592548 Jayaraman Jul 2003 B2
6592614 Lenker et al. Jul 2003 B2
6592615 Marcade et al. Jul 2003 B1
6607552 Hanson Aug 2003 B1
6613073 White et al. Sep 2003 B1
6616675 Evard et al. Sep 2003 B1
6652579 Cox et al. Nov 2003 B1
6656213 Solem Dec 2003 B2
6663665 Shaolian et al. Dec 2003 B2
6669718 Besselink Dec 2003 B2
6669719 Wallace et al. Dec 2003 B2
6676666 Vrba et al. Jan 2004 B2
6702843 Brown et al. Mar 2004 B1
6733523 Shaolian et al. May 2004 B2
6755855 Yurek et al. Jun 2004 B2
6761733 Chobotov et al. Jul 2004 B2
6767359 Weadcock Jul 2004 B2
6790224 Gerberding Sep 2004 B2
6818014 Brown et al. Nov 2004 B2
6821292 Pazienza et al. Nov 2004 B2
6840950 Stanford et al. Jan 2005 B2
6846316 Abrams Jan 2005 B2
6858038 Heuser Feb 2005 B2
6887249 Houser et al. May 2005 B1
6887251 Suval May 2005 B1
6899727 Armstrong et al. May 2005 B2
6899728 Phillips et al. May 2005 B1
6923829 Boyle et al. Aug 2005 B2
6929661 Bolduc et al. Aug 2005 B2
6932837 Amplatz et al. Aug 2005 B2
6939368 Simso Sep 2005 B2
6939371 Kugler et al. Sep 2005 B2
6939377 Jayaraman et al. Sep 2005 B2
6942692 Landau et al. Sep 2005 B2
6942693 Chouinard et al. Sep 2005 B2
6953475 Shaolian et al. Oct 2005 B2
6955679 Hendricksen et al. Oct 2005 B1
6960217 Bolduc Nov 2005 B2
6981982 Armstrong et al. Jan 2006 B2
6984244 Perez et al. Jan 2006 B2
6991639 Holman et al. Jan 2006 B2
6994722 DiCarlo Feb 2006 B2
7004926 Navia et al. Feb 2006 B2
7004964 Thompson et al. Feb 2006 B2
7004967 Chouinard et al. Feb 2006 B2
7014653 Ouriel et al. Mar 2006 B2
7025779 Elliott Apr 2006 B2
7029496 Rakos et al. Apr 2006 B2
7074236 Rabkin et al. Jul 2006 B2
7122051 Dallara et al. Oct 2006 B1
7122052 Greenhalgh Oct 2006 B2
7125464 Chobotov et al. Oct 2006 B2
7144422 Rao Dec 2006 B1
7160318 Greenberg et al. Jan 2007 B2
7162302 Wang et al. Jan 2007 B2
7163715 Kramer Jan 2007 B1
7175652 Cook et al. Feb 2007 B2
7175657 Khan et al. Feb 2007 B2
7189256 Smith Mar 2007 B2
7201770 Johnson et al. Apr 2007 B2
7220276 Williams et al. May 2007 B1
7235095 Haverkost et al. Jun 2007 B2
7244444 Bates Jul 2007 B2
7261733 Brown et al. Aug 2007 B1
7264631 DiCarlo Sep 2007 B2
7264632 Wright et al. Sep 2007 B2
7267685 Butaric et al. Sep 2007 B2
7270675 Chun et al. Sep 2007 B2
7285130 Austin Oct 2007 B2
7314481 Karpiel Jan 2008 B2
7314483 Landau et al. Jan 2008 B2
7320703 DiMatteo et al. Jan 2008 B2
7491230 Holman et al. Feb 2009 B2
7520895 Douglas et al. Apr 2009 B2
7553324 Andreas et al. Jun 2009 B2
7572289 Sisken et al. Aug 2009 B2
7591832 Eversull et al. Sep 2009 B2
7618398 Holman et al. Nov 2009 B2
7637932 Bolduc et al. Dec 2009 B2
7641684 Hilaire et al. Jan 2010 B2
7651519 Dittman Jan 2010 B2
7674284 Melsheimer Mar 2010 B2
7691135 Shaolian et al. Apr 2010 B2
7695508 Van Der Leest et al. Apr 2010 B2
7722657 Hartley May 2010 B2
7785340 Heidner et al. Aug 2010 B2
7833259 Boatman Nov 2010 B2
20020049412 Madrid et al. Apr 2002 A1
20020123786 Gittings et al. Sep 2002 A1
20030004560 Chobotov et al. Jan 2003 A1
20030097169 Brucker et al. May 2003 A1
20030236565 DiMatteo et al. Dec 2003 A1
20040167618 Shaolian et al. Aug 2004 A1
20040176832 Hartley Sep 2004 A1
20050033403 Ward et al. Feb 2005 A1
20050038494 Eidenschink Feb 2005 A1
20050049672 Murphy Mar 2005 A1
20050058327 Pieper Mar 2005 A1
20050059994 Walak et al. Mar 2005 A1
20050060025 Mackiewicz et al. Mar 2005 A1
20050113693 Smith et al. May 2005 A1
20050113905 Greenberg et al. May 2005 A1
20050119731 Brucker et al. Jun 2005 A1
20050121043 Abrams Jun 2005 A1
20050121120 Van Dijk et al. Jun 2005 A1
20050159803 Lad et al. Jul 2005 A1
20050165480 Jordan et al. Jul 2005 A1
20050171598 Schaeffer Aug 2005 A1
20050216043 Blatter et al. Sep 2005 A1
20050240153 Opie Oct 2005 A1
20050240258 Bolduc et al. Oct 2005 A1
20050240260 Bolduc Oct 2005 A1
20050273150 Howell et al. Dec 2005 A1
20050288772 Douglas et al. Dec 2005 A1
20060142838 Molaei et al. Jun 2006 A1
20060217794 Ruiz et al. Sep 2006 A1
20060233990 Humphrey et al. Oct 2006 A1
20060233991 Humphrey et al. Oct 2006 A1
20060287713 Douglas et al. Dec 2006 A1
20070010867 Carter et al. Jan 2007 A1
20070027522 Chang et al. Feb 2007 A1
20070027526 Demetriades et al. Feb 2007 A1
20070027531 DiMatteo et al. Feb 2007 A1
20070112420 LaDuca May 2007 A1
20070203571 Kaplan et al. Aug 2007 A1
20070213804 Schaeffer et al. Sep 2007 A1
20070244540 Pryor Oct 2007 A1
20070260302 Igaki Nov 2007 A1
20080071343 Mayberry et al. Mar 2008 A1
20080172122 Mayberry et al. Jul 2008 A1
20090105806 Benjamin et al. Apr 2009 A1
20090259298 Mayberry et al. Oct 2009 A1
20100004730 Benjamin et al. Jan 2010 A1
20100179636 Pham et al. Jul 2010 A1
Foreign Referenced Citations (24)
Number Date Country
0 621 015 Oct 1994 EP
0 659 389 Jun 1995 EP
0 688 545 Dec 1995 EP
0 740 928 Nov 1996 EP
0 747 020 Dec 1996 EP
0 782 841 Jul 1997 EP
0 783 873 Jul 1997 EP
0 783 874 Jul 1997 EP
0 732 088 Apr 2000 EP
1 433 438 Jun 2004 EP
1 038 606 Jul 1998 ES
04-25755 Jan 1992 JP
WO 9424961 Nov 1994 WO
WO 9634580 Nov 1996 WO
WO 9710757 Mar 1997 WO
WO 9718006 May 1997 WO
WO 9745072 Dec 1997 WO
WO 9820812 May 1998 WO
WO 9947077 Sep 1999 WO
WO 9958084 Nov 1999 WO
WO 0067674 Nov 2000 WO
WO 0124732 Dec 2001 WO
WO 02060345 Aug 2002 WO
WO 2005037076 Apr 2005 WO
Related Publications (1)
Number Date Country
20100179638 A1 Jul 2010 US
Divisions (1)
Number Date Country
Parent 09266661 Mar 1999 US
Child 09795993 US
Continuations (2)
Number Date Country
Parent 10690227 Oct 2003 US
Child 12732095 US
Parent 09795993 Feb 2001 US
Child 10690227 US